21 – 40 of 62
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2015
- Cyclin A1 regulates the interactions between mouse hematopoietic stem and progenitor cells and their niches.
- MIR137 is an androgen regulated repressor of an extended network of transcriptional coregulators.
- Heme oxygenase-1 in macrophages controls prostate cancer progression.
- 2014
- Protein kinase A (PKA) pathway is functionally linked to androgen receptor (AR) in the progression of prostate cancer.
- Heme oxygenase-1 derived carbon monoxide permits maturation of myeloid cells.
- The role of PI3K/AKT-related PIP5K1α and the discovery of its selective inhibitor for treatment of advanced prostate cancer.
- 2013
- miR-155 meets the JAK/STAT pathway.
- Expression of cyclin d1 and its association with disease characteristics in bladder cancer.
- Expression and localization of serotonin receptors in human breast cancer.
- CDK1 interacts with RARγ and plays an important role in treatment response of acute myeloid leukemia.
- The lysine specific demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate cancer
- miRNA in mycosis fungoides and skin inflammation.
- Cyclin A1 modulates the expression of vascular endothelial growth factor and promotes hormone-dependent growth and angiogenesis of breast cancer.
- Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer
- Carbon Monoxide Expedites Metabolic Exhaustion to Inhibit Tumor Growth
- Expression of VEGF and Its receptors VEGFR1/VEGFR2 Is Associated with Invasiveness of Bladder Cancer.
- 2012
- The androgen receptor and stem cell pathways in prostate and bladder cancers (Review)
- Overcoming Drug Resistance and Treating Advanced Prostate Cancer.
- DNA Methylation in ATRA-treated Leukemia Cell Lines Lacking a PML-RAR Chromosome Translocation.
- 2011
- LRIG1 and the liar paradox in prostate cancer: a study of the expression and clinical significance of LRIG1 in prostate cancer